tebu-bio is pleased to announce their new partnership for a European distribution of Novabiosis, a US based manufacturer providing cryopreserved primary human cells for the biotechnology, pharmaceutical and medical research fields. Their focus is on Kidney, Intestine, Lung and Liver tissues. They have developed multiple cell types for each organ, an asset for co-culture studies or 3D models development.
Now that the novel coronavirus (2019-nCoV or COVID-19) outbreak has been declared a “public health emergency of international concern” by the WHO, scientists worldwide are being pressured to develop a treatment.
So what’s the first step? Rockland antibodies developed for the 2002 SARS strain (distributed by tebu-bio in Europe) present opportunities for immediate deployment. Antibodies to SARS, like Anti-SARS-CoV Membrane Protein or Anti-SARS-CoV Nucleocapsid Protein may provide the means of detection with the current strain because of their high homology, particularly the sequences within the membrane and nucleocapsid.
For SARS, the ACE2 receptor was identified as a mechanism by which the SARS virus entered cells—and although ACE2 hasn’t been definitively determined as the sole means of entry for the current strain, our antibodies against ACE2 can play a critical piece in understanding the mechanism of infection.
The biomedical community is working urgently to develop novel antibodies specific for 2019-nCov using engineered immunogens; both polyclonal and monoclonal. Rockland unparalleled experience generating SARS antibodies can be leveraged in the development of products that support the study of 2019-nCov. Even after new antibodies specific for COVID-19 are produced, existing antibodies against SARS epitopes should be used as a positive control in various immunoassays, including binding proxy assays.
For speed and risk mitigation purposes, institutions should consider novel 2019-nCoV antibody production at more than one facility. This provides for variation in antibody performance and timing, which is critical for the rapid development of antibodies suitable for functional studies like neutralization and receptor identification.
So tell us… how can we help you help the world in fighting this infectious disease outbreak?
You may also be interested in a broader overview of tebu-bio anti-viral antibodies portfolio, including validated pairs for immunoassay development. Just click on the link below to download our brochure.
Chromatin profiling assays enable the mapping of protein-DNA interactions that influence chromatin modeling and gene expression.
Over the years, Chromatin ImmunoPrecipitation (ChIP) assays became the gold-standard for studying transcription factor–DNA binding interactions, nucleosome dynamics, and epigenetics (ex. histone post-translational modifications (PTMs)). This post aims at introducing the latest evolution of ChIP assays: CUTANA™ CUT&RUN and ChIC assays.
Over the last years, ChIP experts express the need for more sensitivity, faster protocols, and more reproducible results (and ideally starting from less starting cellular material). These expectations led to the emergence of new experimental antibody-based experimental approaches like Chromatin ImmunoCleavage (ChIC) assays, and Cleavage Under Targets and Release Using Nuclease (CUT&RUN) methods.
Time-Resolved Förster Resonance Energy Transfer (TR-FRET) is a robust and homogeneous fluorescence detection technology and a real alternative to ELISA to perform Cell Signalling studies. Based on this improved TR-FRET technology, tebu-bio is pleased to introduce a new product line of high-quality, fully-validated and affordable kits. These ready-to-use Thunder™ kits enable sensitive, simple and rapid measurement of low amounts of specific intracellular phosphorylated and total proteins in cell lysates from adherent or suspension cells.
The main features of these new Thunder™ Cell Signalling Assays are presented in this post.
How does it work?
Even though based on the traditional immuno-assay sandwich principle, the kits use a streamlined protocol wherein the antibody-target sandwich complex is formed in solution in a single addition and incubation step, without any wash steps. This protocol dramatically decreases hands-on time (5 minutes) and enables faster time to results (1-4 hours).
After lysis steps, a pair of antibodies specific for the target protein is added to the lysate sample (Fig.1). One antibody is labeled with a donor fluorophore (a Europium chelate), while the second antibody is labeled with an acceptor fluorophore (a far-red dye). Upon excitation of the Europium chelate at 320 or 340 nm, energy is transferred from the donor to the acceptor fluorophore if they are sufficiently close (within 10 nm) for FRET. This results in the emission by the acceptor of a TR-FRET signal at 665 nm.
Why is TR-FRET a smart alternative to ELISA for cell signalling studies?
OPTIMAL ANTIBODY PAIR SELECTION
- Validated antibodies were selected to guarantee specificity for the target protein.
- Many donor/acceptor fluorophores were tested to select the optimal pair providing the best TR-FRET signal-to-background.
- Extensive testing of labeled antibody pairs using optimized lysis buffers followed by assay optimization were conducted to ensure specificity, reproducibility and optimal TR-FRET assay performance.
All Thunder™ kits are subjected to a stringent validation process using lysates from cells that are treated with pathway-specific activators and inhibitors to further confirm target specificity.
CONFIRMED LOT-TO-LOT CONSISTENCY
All Thunder™ kits are developed, validated and manufactured to ensure lot-to-lot consistency using a functional quality control assay where each new lot is compared to the previous lot.
Thunder™ is an affordable cell-based assay platform that provides easy access to the TR-FRET technology for all researchers looking to quantify low amounts of endogenous proteins in cells.
Most popular targets
- AKT (pan)
- EGFR : Epidermal Growth Factor
- ERK 1/2 : Extracellular signal Regulated Kinase
- STAT3 : Signal Transducer and Activator of Transcription 3
Typical validation data
All it takes is 3 simple steps to complete the workflow of all the TR-FRET Cell Signaling Assays.
Assays can be run using a 2-plate (transfer) protocol:
Or a 1-plate (all-in-one-well) protocol:
Assays are optimized to be run in 96-well or 384-well plates using the same total volume (20µL).
- PHOSPHO-PROTEIN : Measure the relative amounts of a specific phosphorylated target protein.
- TOTAL-PROTEIN : Measure the relative amounts of a target protein regardless of its phosphorylation status. These kits can be used to monitor protein expression levels and for normalization purposes.
- PHOSPHO + TOTAL PROTEIN : Provide a novel opportunity to measure matched phosphorylated and total proteins from separate wells in the same plate.
Try a real alternative to perform your cell signalling studies in a different way!